The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Therapeutic potential of monoacylglycerol lipase inhibitors
Open accessAbstract
Marijuana and aspirin have been used for millennia to treat a wide range of maladies including pain and inflammation. Both cannabinoids, like marijuana, that exert anti-inflammatory action through stimulating cannabinoid receptors, and cyclooxygenase (COX) inhibitors, like aspirin, that suppress pro-inflammatory eicosanoid production have shown benefitial outcomes in mouse models of neurodegenerative diseases and cancer. Both cannabinoids and COX inhibitors, however, have untoward effects that discourage their chronic usage, including cognitive deficits and gastrointestinal toxicity, respectively. Recent studies have uncovered that the serine hydrolase monoacylglycerol lipase (MAGL) links the endocannabinoid and eicosanoid systems together through hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG) to provide the major arachidonic acid (AA) precursor pools for pro-inflammatory eicosanoid synthesis in specific tissues. Studies in recent years have shown that MAGL inhibitors elicit anti-nociceptive, anxiolytic, and anti-emetic responses and attenuate precipitated withdrawal symptoms in addiction paradigms through enhancing endocannabinoid signaling. MAGL inhibitors have also been shown to exert anti-inflammatory action in the brain and protect against neurodegeneration through lowering eicosanoid production. In cancer, MAGL inhibitors have been shown to have anti-cancer properties not only through modulating the endocannabinoid—eicosanoid network, but also by controlling fatty acid release for the synthesis of protumorigenic signaling lipids. Thus, MAGL serves as a critical node in simultaneously coordinating multiple lipid signaling pathways in both physiological and disease contexts. This review will discuss the diverse (patho)physiological roles of MAGL and the therapeutic potential of MAGL inhibitors in treating a vast array of complex human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.021 · Cited by 472 · cited 6×
“Studies have also shown that retrograde endocannabinoid signaling to suppress GABA-mediated transmission at inhibitory synapses, a phenomenon known as depolarization induced suppression of inhibition (DSI), is absent in DAGL α but not DAGL β-deficient mouse brain, indicating that DAGL α is the more relevant enzyme for…”
BackgroundInfluentialBlockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155465 · Cited by 330
Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288
Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., & Samad, T. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.001 · Cited by 223
Self-citationEffects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
Costa, B., Colleoni, M., Conti, S., Trovato, A. E., Bianchi, M., Sotgiu, M. L., & Giagnoni, G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705587 · Cited by 89 · cited 1×
“In addition to these clinical avenues, both CB1 and CB2 agonists have also been shown to exert anti-nociceptive and anti-inflammatory actions in various rodent models of neuropathic pain and inflammation (Bridges et al., 2001; Costa et al., 2004; Fox et al., 2001; Ibrahim et al., 2003; Kinsey et al., 2011a; Quartilho…”
Background
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Lipase Inhibitors for Obesity: A Review
Liu, T.-T., Liu, X.-T., Chen, Q.-X., & Shi, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110314 · Cited by 403
Metadata
- Authors
- Mulvihill, M. M., & Nomura, D. K.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 92
- Issue
- 8-9
- Pages
- 492-497
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W1971199570
- Cited by
- 196
- References
- 15
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.